227 related articles for article (PubMed ID: 28075467)
1. Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway.
Gao F; Deng G; Liu W; Zhou K; Li M
Oncol Rep; 2017 Feb; 37(2):1203-1211. PubMed ID: 28075467
[TBL] [Abstract][Full Text] [Related]
2. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
[TBL] [Abstract][Full Text] [Related]
3. Trans-resveratrol, a grapevine-derived polyphenol, blocks hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells.
De Lédinghen V; Monvoisin A; Neaud V; Krisa S; Payrastre B; Bedin C; Desmoulière A; Bioulac-Sage P; Rosenbaum J
Int J Oncol; 2001 Jul; 19(1):83-8. PubMed ID: 11408926
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol inhibited the progression of human hepatocellular carcinoma by inducing autophagy via regulating p53 and the phosphoinositide 3‑kinase/protein kinase B pathway.
Zhang B; Yin X; Sui S
Oncol Rep; 2018 Nov; 40(5):2758-2765. PubMed ID: 30132535
[TBL] [Abstract][Full Text] [Related]
5. C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway.
Zhao M; Wang Y; Liu Y; Zhang W; Liu Y; Yang X; Cao Y; Wang S
Cancer Biol Ther; 2019; 20(12):1430-1442. PubMed ID: 31441380
[TBL] [Abstract][Full Text] [Related]
6. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.
Tan S; Li R; Ding K; Lobie PE; Zhu T
FEBS Lett; 2011 Jul; 585(14):2229-34. PubMed ID: 21658389
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.
Liu Y; Tan J; Ou S; Chen J; Chen L
Invest New Drugs; 2020 Feb; 38(1):60-69. PubMed ID: 30929159
[TBL] [Abstract][Full Text] [Related]
8. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling.
Yu J; Xia X; Dong Y; Gong Z; Li G; Chen GG; Lai PBS
Theranostics; 2021; 11(5):2123-2136. PubMed ID: 33500715
[No Abstract] [Full Text] [Related]
9. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
García-Vilas JA; Medina MÁ
World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
[TBL] [Abstract][Full Text] [Related]
10. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
11. LINC00240 sponges miR-4465 to promote proliferation, migration, and invasion of hepatocellular carcinoma cells via HGF/c-MET signaling pathway.
Bu WJ; Fang Z; Li WL; Wang X; Dong MJ; Tao QY; Zhang L; Xu YQ
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10452-10461. PubMed ID: 33155201
[TBL] [Abstract][Full Text] [Related]
12. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
13. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.
Wu JR; Hu CT; You RI; Ma PL; Pan SM; Lee MC; Wu WS
PLoS One; 2015; 10(1):e0114495. PubMed ID: 25607934
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.
Gui Y; Khan MGM; Bobbala D; Dubois C; Ramanathan S; Saucier C; Ilangumaran S
World J Gastroenterol; 2017 Sep; 23(36):6639-6649. PubMed ID: 29085209
[TBL] [Abstract][Full Text] [Related]
15. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
16. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
17. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.
Bozkaya G; Korhan P; Cokaklı M; Erdal E; Sağol O; Karademir S; Korch C; Atabey N
Mol Cancer; 2012 Sep; 11():64. PubMed ID: 22962849
[TBL] [Abstract][Full Text] [Related]
18. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
19. Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.
Yin Y; Guo J; Teng F; Yu L; Jiang Y; Xie K; Jiang M; Fang J
Drug Des Devel Ther; 2019; 13():4173-4184. PubMed ID: 31849449
[TBL] [Abstract][Full Text] [Related]
20. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]